Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor

American Journal of Therapeutics
A WheltonG S Geis

Abstract

The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis. Conventional treatment for these debilitating conditions routinely involves the use of conventional nonsteroidal anti-inflammatory drugs (NSAIDs), which are nonspecific inhibitors of COX-1 and COX-2. Numerous studies suggest that inhibition of renal prostaglandin synthesis by NSAIDs is deleterious to kidney function, particularly in high-risk patients. As celecoxib inhibits COX-2 and spares COX-1 at therapeutic doses, we hypothesized that it may offer an improved renal safety profile in patients at risk for NSAID-induced renal toxicity. This article represents a post hoc analysis of the renal safety of celecoxib, using the safety database generated during its clinical development program. This analysis includes data from more than 50 clinical studies involving more than 13,000 subjects. Most subjects were enrolled in randomized, controlled trials (of up to 12 weeks' duration); however, more than 5000 subjects received celecoxib for as long as 2 years in a long-term, open-label study at as much as twice the maximum recommended dosage. The overall incidence of renal adverse events ...Continue Reading

Citations

Jul 2, 2002·The American Journal of Geriatric Cardiology·G E Sander
Jun 27, 2002·Expert Opinion on Investigational Drugs·Richard J Misischia, Larry W Moreland
Sep 29, 2005·American Journal of Physiology. Renal Physiology·Wenling YeTianxin Yang
Oct 2, 2007·Nature Clinical Practice. Rheumatology·Burkhard HinzKay Brune
May 1, 2008·Expert Review of Clinical Immunology·Andrei Calin
Nov 19, 2010·Postgraduate Medicine·H Richard Barthel, Robert A Axford-Gatley
Oct 7, 2011·The Cochrane Database of Systematic Reviews·Jonathan L MarksChristopher J Edwards
Nov 22, 2013·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Rodolfo V Curiel, James D Katz
Mar 10, 2017·Pharmaceutical Biology·Shafique AhmadKiran Dubey
Mar 17, 2001·Scandinavian Journal of Rheumatology·F McKennaG S Geis
Mar 3, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Gregory L BradenMichael J Germain
Jun 18, 2002·Journal of the American Geriatrics Society·UNKNOWN AGS Panel on Persistent Pain in Older Persons
Aug 11, 2001·The New England Journal of Medicine·G A FitzGerald, C Patrono
Dec 7, 2006·Pain Practice : the Official Journal of World Institute of Pain·Pedro F Bejarano, Juan F Herrero
Jul 28, 2004·European Journal of Clinical Pharmacology·Deborah LaytonSaad A W Shakir
Jun 18, 2004·The New England Journal of Medicine·James R O'Dell
Jun 7, 2005·Expert Opinion on Drug Safety·Michel Burnier
Oct 17, 2009·Expert Opinion on Drug Safety·Sam Harirforoosh, Fakhreddin Jamali
Mar 5, 2016·Expert Opinion on Investigational Drugs·Nikolaos PapageorgiouDimitris Tousoulis
Mar 24, 2016·Journal of the American Society of Nephrology : JASN·Fei WangTianxin Yang
Feb 5, 2002·Expert Opinion on Pharmacotherapy·A Bennett, I A Tavares
Mar 5, 2004·American Journal of Therapeutics·Robert L Barkin, Asokumar Buvanendran
Nov 26, 2002·British Journal of Clinical Pharmacology·Christopher CuttsSusan Tett
Feb 22, 2002·Current Opinion in Nephrology and Hypertension·Ravinder K Wali, William L Henrich
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Raymond C Harris, Matthew D Breyer
Nov 5, 2010·American Journal of Therapeutics·Andrew Whelton, Allan Gibofsky
Jan 5, 2002·The New England Journal of Medicine·C M Nzerue
Jan 18, 2003·Current Hypertension Reports·Hui-Fang Cheng, Raymond C Harris
Apr 10, 2002·American Journal of Therapeutics·W Stewart Hillis
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Burkhard Hinz, Kay Brune
Apr 12, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gary Noroian, David Clive
Oct 14, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·D Francois
Dec 6, 2017·Postgraduate Medicine·Chris Walker, Luigi M Biasucci
Oct 5, 2006·Current Opinion in Anaesthesiology·T Samad, S Abdi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.